Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Inclusion Criteria

• •Patient should fully know and understand the content of consent form, and the patient is willing and able to sign an informed consent form
• •Chinese outpatients with confirmed T2DM
• •Patients of ≥ 18, \< 80 years old
• •Patients currently use metformin monotherapy ≥ 1500 mg/day or maximum tolerable dose and whose glucose levels are not adequately controlled
• •HbA1c ≥ 7% and \< 12%
• •New user\* linagliptin or acarbose as combination therapy with metformin ≥ 1500 mg/day or maximum tolerable dose \*New user defined as a T2DM patient initiating linagliptin or acarbose as an add-on therapy.
• •These are patients who are on metformin and whose glucose levels are not adequately controlled.